Autor(en)
Teich, Niels; Ludewig, Clara; Schmelz, Renate; Bästlein, Elke Christiane; Geißler, Sven; Nagl, Sandra; Walldorf, Jens; Krause, Thomas; Maaser, Christian; Mohl, Wolfgang; Wedemeyer, Heiner H; Bauer, Tilman; Büning, Carsten; Grunert, Philip; Hasselblatt, Peter; Hänschen, Markus; Kahl, Matthias; Engelke, Olaf; Schubert, Stefan; Holler, Babett; Streetz, Konrad; von Arnim, Ulrike; Schmidt, Karen; Stallmach, Andreas; Maul, Jochen; Schweitzer, Axel; Breit, Wolfgang; Hofer, Jan-Hinnerk; Eisold, Marc; Mroß, Michael R; Howaldt, Stefanie; Strobl, Stefanie; Ehehalt, Robert; Schmidt, Klaus; Triller, Carsten; Aymaz, Serhat; Brechmann, Thorsten; Dignaß, Axel; Schnoy, Elisabeth; Swarovsky, Bernd; Gerhard, Birgit; Zink, Doris; Finger, Ulrich; Heil, Franz Josef; Franke, Gerd-Rüdiger; Böhm, Günther; Hunkemöller, Jens; Schmidt-Lauber, Martin; Vonderach, Mirko; Mensler, Olaf; Kunz, Rainer; Kölble, Richard; Rother, Christoph; Klönne, Ulf; Graefe, Ulrich; Schwarz, Wolfgang; Schmitz, Georg; Vibrans, Hans; Witthöft, Thomas; Klugmann, Tobias; Reuther, Martin; Bülow, Frank; Ising, Carsten; Balzer, Christoph; Morgenstern, Julia; Casper, Markus; Winograd, Ron; Pickartz, Tilman; Wagner, Marco; Schmidt, Christoph; Vogt, Wolfgang; Blau, Sabine; Seipel, Rolf; Felten, Gisela; Reuken, Philipp A; Kapp, Jörg; Gemeinhardt, Maximilian; Metzler, Jörg Christian; Hoffstadt, Martin; Wüchner-Hofmann, Susanne
Titel
Effects of SARS-CoV-2 infection on symptoms and therapy of inflammatory bowel disease
Teil von
  • Zeitschrift fur Gastroenterologie, 2021-11-01, Vol.59 (11), p.1189-1196
Ort / Verlag
STUTTGART: Thieme Medical Publishers
Links zum Volltext
Quelle
Scopus
Beschreibungen
Introduction The influence of a SARS-CoV-2 infection on inflammatory bowel disease (IBD) has not yet been well characterized and it is unclear whether this requires an adaptation of the immunosuppressive therapy. Methods A national register was established for the retrospective documentation of clinical parameters and changes in immunosuppressive therapy in SARS-CoV-2 infected IBD patients. Results In total, only 3 of 185 IBD patients (1.6 %) were tested for SARS-CoV-2 infection because of abdominal symptoms. In the course of COVID-19 disease, 43.5 % developed diarrhea, abdominal pain or hematochezia (risk of hospitalization with vs. without abdominal symptoms: 20.0 % vs. 10.6 %, p < 0.01). With active IBD at the time of SARS-CoV-2 detection, there was an increased risk of hospitalization (remission 11.2 %, active IBD 23.3 % p < 0.05). IBD-specific therapy remained unchanged in 115 patients (71.4 %); the most common change was an interruption of systemic therapy (16.2 %). Discussion New abdominal symptoms often appeared in SARS-CoV-2 infected IBD patients. However, these only rarely led to SARS-CoV-2 testing. A high IBD activity at the time of SARS-CoV-2 detection was associated with an increased risk of hospitalization.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX
Die Universität der Informationsgesellschaft